​Tomasz M. Beer, MD, FACP, deputy director, Knight Cancer Institute, Oregon Health and Science University, discusses the potential for genomic tests to result in new treatments.
Tomasz M. Beer, MD, FACP, deputy director, Knight Cancer Institute, Oregon Health and Science University, discusses the potential for genomic tests to result in new treatments. Beer says if a target such as a DNA repair mutation is identified in a patient, then treatments targeting that defect can be prescribed.
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More